684 related articles for article (PubMed ID: 29533873)
1. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
2. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
Umamaheswari A; Puratchikody A; Hari N
Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity.
Pidugu VR; Yarla NS; Pedada SR; Kalle AM; Satya AK
Bioorg Med Chem; 2016 Nov; 24(21):5611-5617. PubMed ID: 27665180
[TBL] [Abstract][Full Text] [Related]
6. Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity.
Huong TT; Dung DT; Huan NV; Cuong LV; Hai PT; Huong LT; Kim J; Kim YG; Han SB; Nam NH
Bioorg Chem; 2017 Apr; 71():160-169. PubMed ID: 28196602
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
Tang G; Wong JC; Zhang W; Wang Z; Zhang N; Peng Z; Zhang Z; Rong Y; Li S; Zhang M; Yu L; Feng T; Zhang X; Wu X; Wu JZ; Chen L
J Med Chem; 2014 Oct; 57(19):8026-34. PubMed ID: 25238284
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.
Marson CM; Matthews CJ; Yiannaki E; Atkinson SJ; Soden PE; Shukla L; Lamadema N; Thomas NS
J Med Chem; 2013 Aug; 56(15):6156-74. PubMed ID: 23829483
[TBL] [Abstract][Full Text] [Related]
10. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
[TBL] [Abstract][Full Text] [Related]
11. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L
Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors.
Routholla G; Pulya S; Patel T; Abdul Amin S; Adhikari N; Biswas S; Jha T; Ghosh B
Bioorg Chem; 2021 Sep; 114():105050. PubMed ID: 34120025
[TBL] [Abstract][Full Text] [Related]
14. Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity.
Heimburg T; Kolbinger FR; Zeyen P; Ghazy E; Herp D; Schmidtkunz K; Melesina J; Shaik TB; Erdmann F; Schmidt M; Romier C; Robaa D; Witt O; Oehme I; Jung M; Sippl W
J Med Chem; 2017 Dec; 60(24):10188-10204. PubMed ID: 29190092
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis and Evaluation of Novel 3/4-((Substituted benzamidophenoxy) methyl)-N-hydroxybenzamides/propenamides as Histone Deacetylase Inhibitors and Antitumor Agents.
Anh DT; Thuan NT; Hai PT; Huong LT; Yen NTK; Han BW; Park EJ; Choi YJ; Kang JS; Hue VTM; Han SB; Nam NH
Anticancer Agents Med Chem; 2019; 19(4):546-556. PubMed ID: 30426904
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
Chen C; Hou X; Wang G; Pan W; Yang X; Zhang Y; Fang H
Eur J Med Chem; 2017 Jun; 133():11-23. PubMed ID: 28371677
[TBL] [Abstract][Full Text] [Related]
18. Discovery of the first histone deacetylase 6/8 dual inhibitors.
Olson DE; Wagner FF; Kaya T; Gale JP; Aidoud N; Davoine EL; Lazzaro F; Weïwer M; Zhang YL; Holson EB
J Med Chem; 2013 Jun; 56(11):4816-20. PubMed ID: 23672185
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity.
Trivedi P; Adhikari N; Amin SA; Bobde Y; Ganesh R; Jha T; Ghosh B
Eur J Pharm Sci; 2019 Oct; 138():105046. PubMed ID: 31421254
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and evaluation of novel N-hydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents.
Hieu DT; Anh DT; Tuan NM; Hai PT; Huong LT; Kim J; Kang JS; Vu TK; Dung PTP; Han SB; Nam NH; Hoa ND
Bioorg Chem; 2018 Feb; 76():258-267. PubMed ID: 29223029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
